December 11, 2012
The article cited below clearly describes the various stages of Dry and Wet Macular Degeneration.
The following is an idea of how the different stages of AMD can potentially progress:
. Early Stage Dry AMD
. Intermediate Stage Dry AMD
. Late Stage Dry AMD Also called “Geographic Atrophy”
. Predominantly classic
. Minimally classic
Understanding and treating AMD of any form is important. Early supplementation and health conscientiousness are your greatest defenses against the degenerative disease. You can slow down AMD’s progression.
For more info:
August 13, 2012
University of Kentucky researchers, led by Dr. Jayakrishna Ambati, have made an exciting finding in the “dry” form of age-related macular degeneration known as geographic atrophy (GA). GA is an untreatable condition that causes blindness in millions of individuals due to death of retinal pigmented epithelial cells.
Ambati and colleagues found evidence that activity of the inflammasome, IL-18, and MyD88 were all increased in human eyes with GA. They then showed that blocking any of these components could prevent retinal degeneration in multiple disease models. The researchers are excited that blocking these pathways could herald a new potential therapy for GA, for which there is no approved treatment.
For more info:
February 7, 2011
A team of researchers, led by University of Kentucky ophthalmologist Dr. Jayakrishna Ambati, has discovered a molecular mechanism implicated in geographic atrophy, the major cause of untreatable blindness in the industrialized world.
Ambati’s team discovered that an accumulation of a toxic type of RNA, called Alu RNA, causes retinal cells to die in patients with geographic atrophy. In a healthy eye, a “Dicer” enzyme degrades the Alu RNA particles.
“We discovered that in patients with geographic atrophy, there is a dramatic reduction of the Dicer enzyme in the retina,” said Ambati. “When the levels of Dicer decline, the control system is short-circuited and too much Alu RNA accumulates. This leads to death of the retina.”
Ambati’s team developed two potential therapies aimed at preventing geographic atrophy and demonstrated the efficacy of both approaches using laboratory models. The first involves increasing Dicer levels in the retina by “over-expressing” the enzyme. The second involves blocking Alu RNA using an “anti-sense” drug that binds and degrades this toxic substance. UK has filed patent applications for both technologies, and Ambati’s group is preparing to start clinical trials by the end of this year.
Response from the scientific community has been enthusiastic.